We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Apotex wants legal protection from patent infringement liabilities related to the manufacturing and marketing of ranitidine hydrochloride, a generic version of GlaxoSmithKline’s (GSK) Zantac, according to a complaint filed in federal court.
Celgene has filed a patent infringement lawsuit in federal court to block the manufacturing and marketing of generic Thalomid, Barr Laboratories confirmed.
Multiple patent infringement lawsuits filed in federal court by Teva Pharmaceutical against competitors gearing up to market their own generic versions of Zoloft could jeopardize their efforts, legal sources say.
Despite a 28 percent increase in profits and an 11 percent rise in sales, AstraZeneca will cut approximately 3,000 jobs to help with anticipated losses from generic competition, the company announced.
A congressional inquiry called to determine the adequacy of the FDA’s approval process for generic drugs might be a sign of strong support among lawmakers for legislation proposed last month that would create a clear pathway for follow-on biologics, according to industry sources.
The invalidation of a key patent held by Pfizer could open the door to the manufacturing and marketing of atorvastatin tablets, a generic version of Pfizer’s blockbuster cholesterol-lowering drug, Lipitor.
Weeks after congressional leaders convened on Capitol Hill to discuss a bill aimed at stopping anticompetitive agreements between generic and brand drug firms, more legislation has emerged targeting another much-criticized practice — launching authorized generics.
A federal inquiry called to determine the adequacy of the FDA’s approval process for generic drugs might be a sign of strong support among lawmakers for legislation proposed last month that would create a clear pathway for follow-on biologics, according to industry sources.
Weeks after congressional leaders convened on Capitol Hill to discuss a bill aimed at stopping anticompetitive agreements between generic and brand drug firms, more legislation has emerged targeting another much-criticized practice — launching authorized generics.
The U.S. Court of Appeals for the Federal Circuit brushed off an eleventh-hour request by Apotex asking it to reverse a decision it made recently upholding a block on sales of generic Plavix.